Home > Result Summaries: Compounds > zidovudine/lamivudine Result Summaries: zidovudine/lamivudine GSKStudy ID Phase Title Summary (Download) 111950_5 n\a Fractures over time stratified by HIV infection and Antiretroviral Therapy (ART) exposure (0 citation(s)) 112287 N/A Drug Use Investigation for Combivir tablet (HRD Cooperative Investigation) (0 citation(s)) 112290 N/A Special Drug Use Investigation for Combivir tablet (Pregnancy) (HRD Cooperative Investigation) (0 citation(s)) 112872_5 n\a HIV treatment and CVD events - Ingenix. Retrospective Database Analysis of Patients with Human Immunodeficiency Virus (HIV) Treatment and Cardiovascular Disease (CVD) Events (0 citation(s)) 112877_7 N/A Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration (5 citation(s)) 112878_7 N/A Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus (0 citation(s)) 112885_5 N/A Antiretroviral Pregnancy Registry (APR)-Risk of birth defects associated with exposure to GSK HIV drugs during pregnancy (1 citation(s)) 112887_5 N/A Studies using DAD - Effects of different interventions to improve ART-associated dyslipidemia (1 citation(s)) 113039_5 N/A Studies using DAD - Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? (1 citation(s)) 113156_5 N/A Studies using the VA - Studies done under the Oversight Committee for the Evaluation of the metabolic complications of HAART (2 citation(s)) 113329_5 n\a Lactic acid levels in children pre- and perinatally treated with antiretrovirals to prevent HIV transmission (Giaquinto; Hyperlactatemia in infants with in utero exposure to ZDV/3TC ) (2 citation(s)) CNAF3021 Phase 4 Long term follow-up of 2 triple combinations CombivirTM + Ziagen™ and Combivir™ + Viracept™ started in HIV-1 infected antiretroviral therapy naïve subjects within 2 years in study CNAF3007-Ecureuil. (0 citation(s)) COL30267 Phase 3 Initial title: Evaluation of efficacy and safety of combination of Combivir TM(AZT/3TC) and abacavir, in HIV-infected patients with an abacavir-susceptible phenotype and who had received Zerit ® (d4T) and Videx ® (ddl) as first-line treatment with or without non nucleosidic… (1 citation(s)) COL30527 Phase 1 The pharmacokinetics and bioequivalence of lamotrigine capsules and tablets, and effect of food on lamotrigine tablets. (0 citation(s)) NUCB3027 Phase 3 Phase III trial to compare the efficacy of the combination zidovudine/lamivudine taken either as a single tablet of a fixed-dose combination (zidovudine 300 mg/lamivudine 150 mg) twice daily, or as zidovudine (two 100 mg capsules, three times daily) and lamivudine (one 150 mg tablet, twice daily ... (0 citation(s)) NZTA1001 Phase 1 An Evaluation of the Bioequivalence of a Combined Formulated Tablet Compared to Epivir and Retrovir Administered Concurrently and the Effect of Food on Absorption (1 citation(s)) NZTA4001 Phase 4 A Randomized, Multicenter Study of EPIVIR 150mg BID, RETROVIR 200mg TID and a Protease Inhibitor Versus 3TC 150mg/ZDV 300mg Fixed-Dose Tablet Given BID with a Protease Inhibitor in HIV-1 Infected Subjects (2 citation(s)) NZTA4003 Phase 4 A Pharmacokinetic Evaluation of Methadone Following Co-administration with Combivir in Opiate-dependent Subjects (0 citation(s)) NZTA4007 Phase 3 A Phase IIIB, Open-Label, Pilot Study to Evaluate the Efficacy, Tolerability, and Health Care Resource Use in HIV-Infected Incarcerated Subjects Treated Twice Daily for 24 Weeks with COMBIVIR (Lamivudine 150mg/Zidovudine 300mg) plus ZIAGEN (Abacavir) 300mg. (1 citation(s)) ZDVB1003 Phase 1 A phase I study to evaluate the pharmacokinetics and safety of RETROVIR (zidovudine, ZDV) administered orally in combination with EPIVIR™ (lamivudine, 3TC) to HIV-1 infected pregnant women and their offspring. (1 citation(s))
